Chemotherapy-Induced Myelosuppression Treatment Market Set For Moderate Growth, To Reach Value around US$ 9.78 Billion by 2028
Zion Market Research has published a new report titled “Chemotherapy-Induced Myelosuppression Treatment Market by Indication (Anaemia, Neutropenia and Thrombocytopenia); by Drug Class (Thrombopoietic Agents, Erythropoietin Stimulating Agents, Iron Supplements, Growth Factors and Others); by Route of Administration (Injectable and Oral); By Distribution Channel (Retail Pharmacies, Hospital Pharmacies and Online Pharmacies): Global Industry Perspective, Comprehensive Analysis and Forecast.
According to the report, The global chemotherapy-induced myelosuppression treatment market stands at a net worth of US$ 8.06 Billion in 2022, and is predicted to rise at a CAGR of 3.3% over the forecast period to attain a valuation of US$ 9.78 Billion by 2028.
Myelosuppression is a term that refers to suppression of bone marrow. Myelosuppression causes reduced blood cells production due to decreased bone marrow activity. This may lead to reduced levels of all blood cells types like platelets, white blood cells (WBCs), red blood cells (RBCs), and any other blood cells. Pancytopenia is a condition that usually arises due to decrease in all three types of blood cells. Chemotherapy’s major side effect is myelosuppression. Chemotherapy may cause to myelosuppression of mild to severe intensity. Medical attention is needed in case of severe myelosuppression which can be even fatal. Different symptoms of myelosuppression are fatigue, shortness of breath, dizziness, dizziness, infection such as cough, fever, chills in case of decrease in white blood cells and anemia in case of decrease in red blood cells etc. Decrease in platelet count may lead to thrombocytopenia.
The global demand for chemotherapy-induced myelosuppression treatment market is driven by easy availability of cutting-edge treatment options like chemotherapy, radiotherapy, surgeries, along with growing preference for chemotherapy for treating cancer, growing cancer prevalence across the globe, promising drug pipelines, increasing healthcare expenditure, growing health awareness among patients, launch of cost effective biosimilars and increasing disposable income. However, intense competition and loss of patent exclusivity may act as restraining factors for the market growth in the coming years. Extensive drug pipeline and emphasis by pharmaceutical companies on safe and efficient chemotherapy-induced myelosuppression drugs development are projected to bring new growth avenues for market players during the forecast timeframe.
Based on indication, global chemotherapy-induced myelosuppression treatment market is segmented into anaemia, neutropenia and thrombocytopenia. Market was dominated by neutropenia indication segment in 2018 and is projected to retain its dominance over the forecast timeframe. This is because neutropenia is most common side effect resulting from myelosuppression treatment. Severity and complications of neutropenia may be fatal and thus greater attention is given to avoid neutropenia post myelosuppression treatment and thus attributing to large share. Thrombocytopenia segment will register highest growth over the forecast period.
Based on drug class market is segmented into thrombopoietic agents, erythropoietin stimulating agents, iron supplements, growth factors and others. Market was dominated by growth factors drug class segment 2018. On the other hand erythropoietin stimulating agents segment will register highest growth rate during the forecast period.
Based on route of administration, global market is segmented into injectable and oral. Market was dominated by injectable administration route segment in 2018. This is attributed to their higher therapeutic availability as compared to oral drugs.
The distribution channel segment of the chemotherapy-induced myelosuppression treatment market is categorized into retail pharmacies, hospital pharmacies and online pharmacies. Among all distribution channels, retail pharmacies dominated the market in 2018 with largest revenue share. Online pharmacies are expected to witness rapid growth in the years to come.
North America held largest revenue share of the global chemotherapy-induced myelosuppression treatment market in 2018. This large share is attributed to strong commercial sales, favorable reimbursement policies, large cancer patient pool, growing awareness and presence of key players in this region. Europe was second leading regional market in terms of revenue. Availability of developed infrastructure, increasing cancer prevalence, and growing awareness are major factors that support market growth in this region. Asia Pacific region is projected to be rapidly growing regional market for chemotherapy-induced myelosuppression treatment. Increasing cancer prevalence and geriatric population base, economic development, improvement of healthcare infrastructure, increasing disposable income and healthcare spending, growing awareness are major factors attributing to the swift growth in this region. Moderate growth is projected in Latin America region over the forecast period. Middle East and Africa will witness sluggish growth in the coming years.
Major players in chemotherapy-induced myelosuppression treatment market are-
- Teva Pharmaceutical Industries Ltd.
- Amgen Inc.
- Janssen Global Services
- Pfizer Inc.
- Mylan NV
- Mission Pharmacal Company
- Myelo Therapeutics GmbH
- Dova Pharmaceuticals
- Partner Therapeutics
- Novartis AG
The report segment of global chemotherapy-induced myelosuppression treatment market as follows:
Global Chemotherapy-Induced Myelosuppression Treatment Market: Indication
- Neutropenia
- Anaemia
- Thrombocytopenia
Global Chemotherapy-Induced Myelosuppression Treatment Market: By Drug Class
- Growth Factors
- Erythropoietin Stimulating Agents
- Thrombopoietic Agents
- Iron Supplements
- Others
Global Chemotherapy-Induced Myelosuppression Treatment Market: By Route of Administration
- Oral
- Injectable
Global Chemotherapy-Induced Myelosuppression Treatment Market: By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Chemotherapy-Induced Myelosuppression Treatment Market: By Region
- North AmericaThe U.S.Canada
- EuropeFranceThe UKSpainGermanyItalyRest of Europe
- Asia PacificChinaJapanIndiaSouth KoreaSoutheast AsiaRest of Asia Pacific
- Latin AmericaBrazilMexicoRest of Latin America
- Middle East & AfricaGCCSouth AfricaRest of Middle East & Africa
About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us — after all — if you do well, a little of the light shines on us.
Contact Us:
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States Tel: +49–322 210 92714 USA/Canada Toll-Free №1–855–465–4651 Email: sales@zionmarketresearch.com Website: https://www.zionmarketresearch.com